Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Antigenicity Studies of M3S Tumor Necrosis Factor-$\alpha$(M3S TNF), a TNF Mutein

M3S Tumor Necrosis Factor-$\alpha$(M3S TNF)의 항원성

  • 한형미 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 손경희 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 오현정 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 최경백 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 정승태 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 선우연 (독성부 면역독성과, 식품의약품안전본부, 서울특별시 은평구 녹번동 5번지) ;
  • 신남규 (한효과학기술원, 대전광역시 유성구 전민동 461-6) ;
  • 신항철 (한효과학기술원, 대전광역시 유성구 전민동 461-6)
  • Published : 1997.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The antigenic potential of M3S tumor necrosis factor-$\alpha$(M3S TNF), which is a mutated form of TNF(TNF mutein) designed to reduce adverse effects of wild type human TNF, was investigated in the present study. The antigenicity of M3S TNF was examined by conducting active systemic anaphylaxis (ASA) test in guinea pigs, heterologous(mouse-rat) passive cutaneous anaphylaxis(PCA) test and passive hemagglutination(PHA) test. The experimental animals were divided into low, medium, high and the highest dose groups and the groups with or without immunoadjuvant, sensitized according to the appropriate schedule and challenged. In ASA test, when challenged with 120 $\mu\textrm{g}$ /animal, moderate to severe positive anaphylactic responses were observed in groups sensitized with 12 $\mu\textrm{g}$ /animal, 120 $\mu\textrm{g}$ /animal and 120 $\mu\textrm{g}$ /animal+Freund's complete adjuvant. In PCA test, positive responses were observed in the group sensitized with the highest dose emulsified with an alum(12 $\mu\textrm{g}$ /animal+alum). In PHA test, positive responses were observed in the group sensitized with 3 $\mu\textrm{g}$ /animal emulsified with an alum. All the other groups in each experiment showed negative responses. Based on these results, M3S TNF is considered to have some antigenic potential.

Keywords

References

  1. Nature v.320 Cachectin and tumor necrosis factor as two sides of the same biological coin Beulter, B.;Cerami, A.
  2. J. Clin. Oncol. v.5 Clinical phamacology of recombinant human tumor necrosis factor in patients with advanced cancer Chapman, P. B.;Lester, T. J.;Casper, E. S.;Gabrilove, J. L.;Wong, G. Y.;Kempin, S. J.;Gold, P. J.;Welt, S.;Warren, R. S.;Starnes, H. F.;Sherwin, S. A.;Old, L. J.;Oettgen, H. F.
  3. J. Clin. Oncol. v.11 Phase Ⅰclinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors : A pediatric oncology group study Furman, W. L.;Strother, D.;McClain, K.;Bell, B.;Leventhal, B.;Pratt, C. B.
  4. J. Biological Modifiers v.8 Antitumor effect of systemic administration of novel recombinant tumor necrosis factor(rTNF-S) with less toxicity than conventional rTNF-α in vivo Gatanaga, T.;Noguchi, K.;Tanabe, Y.;Inagawa, H.;Soma, G.;Mizuno, D.
  5. Clin. Exp. Metastasis v.10 Injection of recombinant tumor necrosis factor directly into liver metastases : An experimental and clinical approach IJzermans, J.N.M.;Scheringa, M.;van der Schelling, G.P.;Geerling, R.A.;Marquet, R.L.;Jeekel, J.
  6. Int. J. Cancer v.48 A novel recombinant tumor necrosis factor-alpha mutant with increased anti-tumor activity and lower toxicity Nakamura, S.;Kato, A.;Masegi, T.;Fukuoka, M.;Kitai, K.;Ogawa, H.;Ichikawa, Y.;Maeda, M.;Watanabe, N.;Kohgo, Y.;Nutsu, Y.
  7. Science v.230 Tumor necrosis factor(TNF) Old, L.J.
  8. J. Cell. Biol. v.107 Cachectin/tumor necrosis factor exerts endocrine, paracrine and autocrine control of inflammatory responses Sherry, B.;Cerami, A.
  9. J. Immunotherapy v.10 Phase Ⅰ evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma Smith Ⅱ, J.W.;Urba, W.J.;Clark, J.W.;Longo, D.L.;Farrel, M.;Creekmore, S.P.;Conlon, K.C.;Jaffe, H.;Steis, R.G.
  10. J. the National Cancer Institute v.80 Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion : A phase I and pharmacologic study Spriggs, D. R.;Sherman, M.L.;Michie, H.;Arther, K.A.;Imamura, K.;Wilmore, D.;Frei, E.Ⅲ;Kufe, D. W.
  11. Eur. J. Cancer v.28A A Phase Ⅰ study of local treatment of liver metastases with recombinant tumor necrosis factor Van der Schelling;G.P. IJzermans, J.N.M.;Kok, T.C.;Scheringa, M.;Marquet, R.L.;Splinter, T.A.W.;Jeekel, J.
  12. J. Cancer Res. Clin. Oncol. v.115 Phase Ⅰ trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas Wiedemann, B.;Reichardt, P.;Rath, U.;Theilmann, L.;Schule, B.;Ho, A.D.;Schlick, E.;Kempeni, J.;Hunstein, W.;Kommerell, B.
  13. Cancer Res. v.51 Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor-α in patients with advanced non-small cell lung cancer : A PhaseⅠ Trial Yang, S.C.;Grimm, E.A.;Parkinson, D.R.;Carinhas, J.;Fry, K.D.;Rodriguez, A.M.;Licciardello, J.;Owen-Schaub, L.B.;Hong, W.K.;Roth, J.A.